Rhythm Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity.
Rhythm Pharmaceuticals stock last closed at $65.19, down 0.05% from the previous day, and has increased 63.96% in one year. It has overperformed other stocks in the Biotechnology industry by 1.41 percentage points. Rhythm Pharmaceuticals stock is currently +85.36% from its 52-week low of $35.17, and -4.94% from its 52-week high of $68.58.
At the moment, there are 63.22M RYTM shares outstanding. The market capitalization of RYTM is $4.12B. In the past 24 hours, 402,296 RYTM shares were traded.
How to Buy Rhythm Pharmaceuticals Stock
Not sure how to invest in Rhythm Pharmaceuticals stock? Here's how.
Figure out where to buy Rhythm Pharmaceuticals stock: You need to decide on a stock brokerage, but don't worry - we've tried dozens of stock brokerages and apps to help you figure out where to buy Rhythm Pharmaceuticals stock.
Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
Fund your investment account: Pick your method of payment and add your info.
Research Rhythm Pharmaceuticals stock: The Rhythm Pharmaceuticals ticker symbol is RYTM. Is Rhythm Pharmaceuticals stock a good investment? Should you buy shares of RYTM? How do RYTM's underlying business fundamentals look? Do top analysts think Rhythm Pharmaceuticals is a good buy? Why has RYTM's stock price moved recently? (Hint: Our stock market research website can help you decide if RYTM is a good stock to buy).
Execute your RYTM purchase: Decide if you will purchase RYTM shares at the current market price or use a limit order to purchase RYTM shares at a given price.
Keep an eye on your investment in RYTM: Create a watchlist to get live updates on your new investment in Rhythm Pharmaceuticals stock.
Step 1: Figure out where to buy Rhythm Pharmaceuticals stock
You need an online brokerage account to access the NASDAQ market and buy RYTM shares.
A brokerage account is an investment account that allows you to buy and sell a variety of investments, including stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
In our opinion, eToro is the best place to buy stocks. Here's why:
You can invest in stocks with 0% commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
Access to world markets: From Tech to Energy, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
Social investing: eToro offers a community of more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of other investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by creating an account with eToro now. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Sign up for your brokerage account
Now that you've chosen the best brokerage, you need to fill out some personal information so you are able to invest in RYTM stock today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Research Rhythm Pharmaceuticals stock
Once you have figured out the best place to buy Rhythm Pharmaceuticals stock, it's very important to research their stock before you buy, so you can wrap your head around the risk and upside.
Rhythm Pharmaceuticals Numbers
RYTM Price
$65.19
1w %
8.94%
1y %
63.96%
5y %
246.02%
P/E
-15.02x
P/B
189.68x
P/S
30.56x
PEG
N/A
Revenue
$130.13M
Earnings
-$264.57M
Fore. Rev. Growth
58.91%
Fore. Earn. Growth
N/A
Market Cap
$4.12B
Next Earnings
May 5, 2025
Next Dividend
N/A
RYTM Due Diligence Checks
WallStreetZen was created to help everyday investors perform better fundamental analysis.
RYTM has cash burn of 113879000. It has enough cash and short-term investments to cover this for at least one year.
RYTM has $321.03M in cash and short term investments. This is enough to cover its annual cash burn of $113.88M.
There are more short-term assets than long-term liabilities on the RYTM balance sheet.
There are more short-term assets than short-term liabilities on the RYTM balance sheet.
Negative Health Checks:
RYTM has a relatively high debt to equity ratio of 10.48.
RYTM profit margin has gone up by 0.35 percentage points in the past year, but the company is still unprofitable.
Total RYTM debt is higher than 5 years ago, relative to shareholder equity.
Is it a good time to buy RYTM stock, according to analysts?
Out of 11 sell side analysts who research RYTM, the consensus analyst rating on Rhythm Pharmaceuticals is a Strong Buy
Please keep in mind that analyst ratings are not stock recommendations, nor are they financial advice.
Latest RYTM Analyst Upgrades/Downgrades
Jeffrey Hung, a top 18% analyst from Morgan Stanley assumes RYTM with a strong buy rating and maintains their RYTM price target from $72.00 to $72.00, on Mar 7, 2025.
Paul Matteis, a bottom 4% analyst from Stifel Nicolaus reinstates RYTM with a strong buy rating and announces their RYTM price target of $78.00, on Mar 5, 2025.
Jonathan Wolleben, a top 8% analyst from JMP Securities reiterates RYTM with a buy rating and maintains their RYTM price target from $75.00 to $75.00, on Dec 23, 2024.
Leland Gershell, a top 6% analyst from Oppenheimer initiates coverage on RYTM with a buy rating and announces their RYTM price target of $76.00, on Dec 20, 2024.
Corinne Jenkins, a top 31% analyst from Goldman Sachs maintains RYTM with a strong buy rating and raises their RYTM price target from $59.00 to $66.00, on Dec 5, 2024.
Last year, RYTM revenue was $130.13M. During the last three year, RYTM's revenue has gone up by 342.73% per year. This was faster than the Biotechnology industry average of 45.66%.
Over the past 12 months, executives and large shareholders at RYTM have sold more shares than they have bought.
Pamela J. Cramer, Chief Human Resources Officer of RYTM, was the latest RYTM insider to sell. They sold $402,000.00 worth of RYTM shares on Apr 8, 2025.
No, Rhythm Pharmaceuticals doesn't provide an income stream by paying out dividends.
What do other traders have to say about RYTM?
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Execute your RYTM purchase
You have two primary types of orders:
Market order: A market order is an order to buy or sell a stock at the best available price. Market orders are mostly the best for newer investors.
Limit order: A limit order allows you to buy or sell a stock at a specific price (or better). If you want to be certain you're buying or selling at a specific price limit, place a limit order.
Hit the Open button and your broker will place your order.
If you need additional info about investing in stocks on eToro, watch the helpful video below:
How much does it cost to buy one Rhythm Pharmaceuticals share?
As of Apr 30, 2025, it costs $65.19 to buy one share of Rhythm Pharmaceuticals stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.153 shares of RYTM.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.